Vir’s mAb on par with Lilly combo in early stage patients

Vir’s COVID mAb has produced some of the strongest data to date in high-risk outpatients, reducing hospitalization or death by 85% (p=0.002).

Vir Biotechnology Inc. (NASDAQ:VIR) and partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) announced Thursday that they were stopping the Phase III COMET-ICE trial of the antiviral mAb VIR-7831 early due to “evidence of profound efficacy.” ...